Fifth Third Bancorp Sells 8,637 Shares of Zoetis Inc. $ZTS

Fifth Third Bancorp lowered its stake in Zoetis Inc. (NYSE:ZTS) by 5.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 162,140 shares of the company’s stock after selling 8,637 shares during the period. Fifth Third Bancorp’s holdings in Zoetis were worth $23,724,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC boosted its holdings in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. NewSquare Capital LLC grew its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. Financial Consulate Inc. acquired a new position in Zoetis in the third quarter valued at about $39,000. SJS Investment Consulting Inc. raised its position in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new position in Zoetis during the 3rd quarter worth approximately $42,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $126.64 on Tuesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a 50-day moving average of $124.59 and a 200 day moving average of $135.21. The company has a market capitalization of $53.46 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.12 and a beta of 0.96.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ZTS shares. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. KeyCorp began coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.